BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 8558200)

  • 1. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest.
    Sharp JG; Kessinger A; Mann S; Crouse DA; Armitage JO; Bierman P; Weisenburger DD
    J Clin Oncol; 1996 Jan; 14(1):214-9. PubMed ID: 8558200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.
    Vose JM; Anderson JR; Kessinger A; Bierman PJ; Coccia P; Reed EC; Gordon B; Armitage JO
    J Clin Oncol; 1993 Oct; 11(10):1846-51. PubMed ID: 8105034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow.
    Talmadge JE; Reed E; Ino K; Kessinger A; Kuszynski C; Heimann D; Varney M; Jackson J; Vose JM; Bierman PJ
    Bone Marrow Transplant; 1997 Jan; 19(2):161-72. PubMed ID: 9116614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.
    Freedman AS; Takvorian T; Anderson KC; Mauch P; Rabinowe SN; Blake K; Yeap B; Soiffer R; Coral F; Heflin L
    J Clin Oncol; 1990 May; 8(5):784-91. PubMed ID: 2332768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique.
    Sharp JG; Joshi SS; Armitage JO; Bierman P; Coccia PF; Harrington DS; Kessinger A; Crouse DA; Mann SL; Weisenburger DD
    Blood; 1992 Feb; 79(4):1074-80. PubMed ID: 1737092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry.
    Williams CD; Pearce R; Taghipour G; Green ES; Philip T; Goldstone AH
    J Clin Oncol; 1994 Nov; 12(11):2415-22. PubMed ID: 7964958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Majolino I; Pearce R; Taghipour G; Goldstone AH
    J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.
    Vose JM; Rizzo DJ; Tao-Wu J; Armitage JO; Bashey A; Burns LJ; Christiansen NP; Freytes CO; Gale RP; Gibson J; Giralt SA; Herzig RH; Lemaistre CF; McCarthy PL; Nimer SD; Petersen FB; Schenkein DP; Wiernik PH; Wiley JM; Loberiza FR; Lazarus HM; van Biesen K; Horowitz MM
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):116-27. PubMed ID: 14750077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral stem cell transplantation in non-Hodgkin's lymphoma patients.
    Kessinger A; Vose JM; Bierman PJ; Bishop M; Armitage JO
    J Hematother; 1993; 2(3):361-2. PubMed ID: 7921996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.
    Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM
    J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
    Vellenga E; van Agthoven M; Croockewit AJ; Verdonck LF; Wijermans PJ; van Oers MH; Volkers CP; van Imhoff GW; Kingma T; Uyl-de Groot CA; Fibbe WE
    Br J Haematol; 2001 Aug; 114(2):319-26. PubMed ID: 11529850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
    Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
    J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry.
    Williams CD; Goldstone AH; Pearce RM; Philip T; Hartmann O; Colombat P; Santini G; Foulard L; Gorin NC
    J Clin Oncol; 1996 Sep; 14(9):2454-64. PubMed ID: 8823323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.
    Sweetenham JW; Pearce R; Taghipour G; Blaise D; Gisselbrecht C; Goldstone AH
    J Clin Oncol; 1996 Sep; 14(9):2465-72. PubMed ID: 8823324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
    Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
    J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.